Zoetis Investors with Significant Losses Invited to Lead Securities Lawsuit
Investors who incurred losses exceeding $100,000 on Zoetis Inc. securities between January 14, 2025, and May 6, 2026, are being invited to serve as lead plaintiff in a securities fraud lawsuit.
Rosen Law Firm has announced a deadline of July 27, 2026, for investors who purchased securities in Zoetis Inc. (NYSE: ZTS) during the period of January 14, 2025, to May 6, 2026, and experienced losses of over $100,000. These investors are potentially eligible to be appointed as the lead plaintiff in a class action lawsuit alleging securities fraud.
The lawsuit claims that Zoetis made false or misleading statements and failed to disclose negative information regarding its key products. Specifically, the complaint alleges that veterinarian prescription growth and adoption rates for the canine pain treatment Librela weakened significantly due to safety concerns highlighted by the FDA. Furthermore, the lawsuit asserts that Zoetis' Simparica Trio product lost substantial market share to a lower-priced competitor.
Additionally, the complaint details an alleged loss of market share for Zoetis' dermatology products, Apoquel and Cytopoint, to a newly launched competing canine treatment. When the true details about these weakening sales and market share losses became public, investors allegedly suffered damages.
Rosen Law Firm, which specializes in investor rights, is encouraging eligible investors to come forward. The firm offers representation on a contingency fee basis, meaning clients would not pay out-of-pocket fees. Interested parties are advised to contact the firm for more information on how to participate in the class action.